팔정산(八正散)으로 하부요로증상이 호전된 양성전립선비대증 환자 4례

Report of Four Cases of Paljung-san on Lower Urinary Tract Symptoms in Patients with Benign Prostatic Hyperplasia

  • 송문구 (경희대학교 한의과대학 신계내과학교실) ;
  • 박성환 (경희대학교 한의과대학 신계내과학교실) ;
  • 강지석 (경희대학교 한의과대학 신계내과학교실) ;
  • 안영민 (경희대학교 한의과대학 신계내과학교실) ;
  • 안세영 (경희대학교 한의과대학 신계내과학교실) ;
  • 김영옥 (농촌진흥청 국립원예특작과학원) ;
  • 이병철 (경희대학교 한의과대학 신계내과학교실)
  • Song, Moon-Koo (Dept. of Internal medicine, College of Oriental Medicine, Kyung Hee University) ;
  • Park, Sung-Hwan (Dept. of Internal medicine, College of Oriental Medicine, Kyung Hee University) ;
  • Kang, Ji-Suck (Dept. of Internal medicine, College of Oriental Medicine, Kyung Hee University) ;
  • Ahn, Young-Min (Dept. of Internal medicine, College of Oriental Medicine, Kyung Hee University) ;
  • Ahn, Se-Young (Dept. of Internal medicine, College of Oriental Medicine, Kyung Hee University) ;
  • Kim, Young-Ock (Department of Herbal Crop Research, National Institute of Horticultural & Herbal Science, Rural Development Administration) ;
  • Lee, Byung-Cheol (Dept. of Internal medicine, College of Oriental Medicine, Kyung Hee University)
  • 투고 : 2009.07.06
  • 심사 : 2009.08.20
  • 발행 : 2010.01.30

초록

Objective: The primary objective of this study was to evaluate the effect of Paljung-san on lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH). Methods: We researched four men with BPH and LUTS, who were treated 3 times a day for 10 days with Paljung-san. The International Prostate Symptom Score (IPSS) and post void residual urine (PVR) were evaluated. Results: The mean decrease in IPSS total score was 13 points (P=0.007, Mann-Whitney test). The reduction of IPSS was more prominent in the obstructive subscore but was not significant (P=0.057, Mann-Whitney test). Furthermore, Paljung-san reduced PVR. Conclusions: After the 10-day treatment period, Paljung-san improved total IPSS score, especially in the obstructive subscale score, and reduced post void residual urine.

키워드

참고문헌

  1. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). chapter 1: Diagnosis and treatment recommendations. J Urol. 2003;170: 530-47. https://doi.org/10.1097/01.ju.0000078083.38675.79
  2. Lee HL, Seo JW, Kim WJ. The prevalence of benign prostatic hyperplasia: Community-based study in chungbuk province. Korean J Urol. 1999;40:1500-5.
  3. Wiygul J, Babayan RK. Watchful waiting in benign prostatic hyperplasia. Curr Opin Urol. 2009;19:3-6. https://doi.org/10.1097/MOU.0b013e32831a6ec6
  4. Kang JY, Kim SI, Lee HW, Seong DH, Cho JS. Change in Patients' Perspectives after Education on the Management of Benign Prostatic Hyperplasia. Korean J Urol. 2009;50(04): 340-8. https://doi.org/10.4111/kju.2009.50.4.340
  5. Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Transurethral prostatectomy: Immediate and postoperative complications. a cooperative study of 13 participating institutions evaluating 3,885 patients. 1989. J Urol. 2002;167:999-1003; discussion 1004. https://doi.org/10.1016/S0022-5347(02)80323-8
  6. Doll HA, Black NA, McPherson K, Flood AB, Williams GB, Smith JC. Mortality, morbidity and complications following transurethral resection of the prostate for benign prostatic hypertrophy. J Urol. 1992;147:1566-73.
  7. Andersson KE. Storage and voiding symptoms: Pathophysiologic aspects. Urology. 2003;62:3-10.
  8. Ahn YM, Ahn SY, Cho DH, Doo HK. The study of oriental and accidental benign prostste hypertrophy. J. of Oriental. Chr. Dis. 1995;1:85- 112.
  9. Kim SM, Yoo DY. A Case Report of the Effects of paljeongsan on the Female Urethral Syndrome. Journal of Oriental Obsterics & Gynecology. 2007;20:225-33.
  10. Lee MS, Lee SH, Song MD. Two cases of Cystitis Patients Trated with Paljung-san. J. of Oriental. Chr. Dis. 2000;6(1):102-5
  11. You SH, Jeong HJ. The Clinical Effects of Amitriptyline on the Nocturia of Patients with Benign Prostatic Hyperplasia. Korean J Urol. 2008;049(04): 343-9. https://doi.org/10.4111/kju.2008.49.4.343
  12. Choi HR, Chung WS, Shim BS, Kwon SW, Honh SJ, Chung BH. Translation validity and reliability of I-PSS korean version. Korean J Urol.1996;37:659-65.
  13. Cho HJ, Kang JY, Yoo TK. The international prostate symptom score: Discrepancies between self-administration and physician-administration. Korean J Urol. 2007;48:500-4. https://doi.org/10.4111/kju.2007.48.5.500
  14. Simpson RJ, Fisher W, Lee AJ, Russell EB, Garraway M. Benign prostatic hyperplasia in an unselected community-based population: A survey of urinary symptoms, bothersomeness and prostatic enlargement. Br J Urol. 1996;77:186-91. https://doi.org/10.1046/j.1464-410X.1996.08593.x
  15. Chung BH, Medical Management for Benign Prostatic Hyperplasia. Korean J Urol 2007;48 (03): 233-43. https://doi.org/10.4111/kju.2007.48.3.233
  16. Seong KW, Ahn YM, Ahn SY, Doo HK. Effect of Yungmijihwang-tang and Bojungikki-tang on the Population Doublings and the Population Doubling Time in Rat Fibroblast, Heart-Endothelial Cells, Mesangial Cells. Korean J. Orint. Int. Med. 2003;24:551-60.
  17. Eum HS, Kim SA, Jung WS, Shin GC, Kang YH. Clinical Report on a Patient with Benign Prostatic Hyperplasia diagnosed as the Deficiency of Yang of the Kidney. The Journal Of The Korea Institute Of Oriental Medical Informatics 2004; 10:8-16.
  18. Kim JK, Song BK, Lee EJ, Kim HK Study on the Treatment of Benign Prostatic Hyperplasia (BPH) in Oriental Medicine. J Korean Oriental Med. 1998;19(2):211-27
  19. 彭懷仁. 中醫方劑大辭典精選本. 北京: 人民衛生 出版社; 1999: 52-3.
  20. Kaplan SA, Wein AJ, Staskin DR, Roehrborn CG, Steers WD. Urinary retention and post-void residual urine in men: Separating truth from tradition. J Urol. 2008;180(1):47-54. https://doi.org/10.1016/j.juro.2008.03.027